Top 10 GLP-1 & Heart Failure Questions from Reddit, Answered

Question 1

What is the difference between HFpEF and HFrEF for GLP-1 decisions, and which one is Zepbound actually approved for?

Accepted Answer

Heart failure splits into two anatomic categories that respond differently to GLP-1 therapy. HFpEF (heart failure with preserved ejection fraction) means the left ventricle pumps with a normal or near-normal ejection fraction of 50% or higher but is stiff and fills poorly; it is overwhelmingly the obesity-associated phenotype. HFrEF (heart failure with reduced ejection fraction) means the left ventricle is weakened with an ejection fraction under 40%, often after ischemic injury, and has its own evidence-based backbone of beta-blockers, ACE/ARB/ARNI, MRA, and SGLT2 inhibitors. The FDA-approved heart failure indication for tirzepatide (Zepbound) is HFpEF in adults with obesity, based on the SUMMIT randomized trial showing reductions in heart failure events and improvements in symptoms (Packer 2025, PMID 39555826). Semaglutide (Wegovy and Ozempic) has positive HFpEF data from STEP-HFpEF (Kosiborod 2023, PMID 37622681) and STEP-HFpEF DM (Kosiborod 2024, PMID 38587233), and a prespecified SELECT analysis showed CV benefit in patients with prevalent heart failure regardless of ejection fraction (Deanfield 2024, PMID 39181597). None of this is medical advice.

Question 2

I have HFpEF with obesity. Should I be on Zepbound, Wegovy, or both?

Accepted Answer

HFpEF plus obesity is the single strongest GLP-1 indication that exists in the heart failure literature today, and both Zepbound and Wegovy have positive randomized data in this exact phenotype. The SUMMIT trial randomized 731 patients with HFpEF and obesity to tirzepatide versus placebo for up to 104 weeks and showed reduced heart-failure events and improved Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom scores (Packer 2025 NEJM, PMID 39555826). The STEP-HFpEF trial randomized 529 patients with HFpEF and obesity without diabetes to semaglutide 2.4 mg weekly versus placebo for 52 weeks and showed substantial improvements in KCCQ symptom score and 6-minute walk distance (Kosiborod 2023 NEJM, PMID 37622681). STEP-HFpEF DM extended the finding to HFpEF patients with type 2 diabetes (Kosiborod 2024 NEJM, PMID 38587233). The pooled Lancet analysis of SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM showed consistent benefit across the spectrum of mildly reduced and preserved ejection fraction (Kosiborod 2024, PMID 39222642). Zepbound is the only one with an FDA-labeled HFpEF indication; Wegovy is used off-label for HFpEF but with strong randomized evidence. Choice usually rests with the cardiologist. None of this is medical advice.

Question 3

I have HFrEF with an EF of 25%. Is a GLP-1 safe for me?

Accepted Answer

HFrEF is the murkier case and the published randomized data are not encouraging. The FIGHT trial randomized 300 patients with advanced HFrEF (mean ejection fraction roughly 25%) and recent hospitalization to liraglutide versus placebo for 180 days and found no clinical benefit and numerically more deaths and rehospitalizations in the liraglutide arm (Margulies 2016 JAMA, PMID 27483064). A secondary FIGHT analysis confirmed weight loss without clinical benefit and showed signals of harm in some subgroups (Sharma 2018 ESC Heart Fail, PMID 30120812). The LIVE trial randomized 241 patients with HFrEF with and without diabetes to liraglutide versus placebo for 24 weeks and found no improvement in left ventricular function and a higher rate of serious cardiac adverse events (Jorsal 2017 Eur J Heart Fail, PMID 27790809). These are liraglutide trials and may not translate one-to-one to semaglutide or tirzepatide, but they are the only randomized HFrEF data we have today. The standard HFrEF backbone of beta-blocker, ACE/ARNI, MRA, and SGLT2 inhibitor remains first-line. GLP-1 use in HFrEF is increasingly described in Reddit threads as a cardiologist-supervised decision, not a default. None of this is medical advice.

Question 4

How much does a GLP-1 raise my heart rate, and does that cancel out the benefit of my beta-blocker?

Accepted Answer

GLP-1 receptor agonists modestly raise resting heart rate, and the effect is consistent enough to be visible in essentially every randomized trial of the class. The 2021 Lancet Diabetes & Endocrinology meta-analysis of GLP-1 cardiovascular outcome trials reported an average resting heart rate increase of roughly 3-4 beats per minute across studies, with semaglutide and dulaglutide at the higher end and exenatide and lixisenatide at the lower end (Sattar 2021, PMID 34425083). Individual patients on Reddit report variability from no detectable change to 10-15 bpm at peak dose, which is consistent with the trial-level standard deviations. For HFpEF, this heart-rate effect is generally clinically tolerated and was not enough to erase the benefits seen in SUMMIT or STEP-HFpEF. For HFrEF, the heart-rate effect matters more because beta-blockade and rate control are load-bearing parts of the disease-modifying backbone and chronic tachycardia worsens outcomes. This is one of the mechanistic reasons FIGHT and LIVE failed to show benefit in HFrEF. Practical pattern in Reddit threads: cardiologists frequently uptitrate the beta-blocker before or alongside GLP-1 initiation in HFrEF patients. None of this is medical advice.

Question 5

My NT-proBNP came back high after starting Wegovy. Does that mean it's making my heart failure worse?

Accepted Answer

A single elevated NT-proBNP or BNP value after starting a GLP-1 does not by itself mean the drug is worsening heart failure, and the randomized HFpEF data actually went the other direction. In STEP-HFpEF, semaglutide 2.4 mg reduced log NT-proBNP versus placebo over 52 weeks alongside symptom and walk-distance improvements (Kosiborod 2023 NEJM, PMID 37622681). In SUMMIT, tirzepatide reduced NT-proBNP and improved cardiac structure on MRI in HFpEF plus obesity (Packer 2025, PMID 39555826; Pandey 2025 SUMMIT CMR substudy, PMID 39566869). Natriuretic peptides are sensitive but not specific markers; they can shift up or down with volume status, hydration, acute illness, renal function, atrial fibrillation, and timing relative to the last diuretic dose. In Reddit threads, the pattern that resolves is usually checking a follow-up value on a stable regimen, sharing the trend with the cardiologist, and not stopping the GLP-1 for a single isolated number. If symptoms (dyspnea on exertion, lower-extremity edema, orthopnea) are worsening, that is a separate clinical signal that needs cardiology review. None of this is medical advice.

Question 6

I'm on Lasix (furosemide) for heart failure. Will Wegovy or Zepbound interact with it or cause dehydration?

Accepted Answer

There is no direct pharmacokinetic interaction between loop diuretics like furosemide (Lasix), bumetanide, or torsemide and the injectable GLP-1 agonists, but there is an important volume-status interaction worth flagging. GLP-1 therapy reduces appetite and fluid intake, accelerates weight loss, and shifts fluid balance in ways that can unmask over-diuresis. In STEP-HFpEF, semaglutide allowed many HFpEF patients to reduce or discontinue loop diuretics over the trial period as their symptoms and volume status improved (Kosiborod 2023, PMID 37622681). The SUMMIT trial showed a similar pattern with tirzepatide reducing the proxy markers of circulatory overload (Borlaug 2025 Nat Med, PMID 39551891). Practical pattern in Reddit threads: patients on chronic loop diuretics for HFpEF or HFrEF often need a dose reassessment 4-12 weeks into GLP-1 therapy because the diuretic dose that fit at 120 kg may over-diurese at 100 kg. Signs to flag to the cardiology team: orthostatic dizziness, rising creatinine, falling sodium, cramping, or excessive thirst. The fix is usually dose reduction of the diuretic, not stopping the GLP-1. None of this is medical advice.

Question 7

Can I be on a GLP-1 plus an SGLT2 inhibitor (Jardiance, Farxiga) plus an ARNI (Entresto) at the same time?

Accepted Answer

Yes, this combination is increasingly the emerging standard for the HFpEF-plus-obesity phenotype and is also common in HFrEF practice, with each drug working through a different mechanism. SGLT2 inhibitors (empagliflozin in EMPEROR-Preserved, dapagliflozin in DELIVER) carry Class I HFpEF recommendations and reduce heart failure hospitalization. ARNI (sacubitril/valsartan) has Class I HFrEF and lower-class HFpEF indications. GLP-1 agonists in HFpEF plus obesity reduce weight, symptoms, and HF events per SUMMIT and the pooled STEP-HFpEF analysis (Packer 2025 PMID 39555826; Kosiborod 2024 Lancet pooled PMID 39222642). The Sattar 2021 meta-analysis confirmed broad cardiovascular benefit of the GLP-1 class in T2D with and without established CV disease (PMID 34425083), and the Lee 2025 Diabetes Care analysis extended the CV/kidney/mortality findings to injectable and oral GLP-1s (PMID 40156846). There is no major pharmacokinetic interaction between these three drug classes. Combination care does require attention to volume status, blood pressure, and renal function. None of this is medical advice.

Question 8

Did the SUMMIT trial actually show Zepbound reverses heart damage, or just makes people feel better?

Accepted Answer

SUMMIT showed both: clinical improvement in HFpEF symptoms and structural improvement on cardiac MRI. The primary SUMMIT publication randomized 731 HFpEF-plus-obesity patients to tirzepatide versus placebo for up to 104 weeks and reported reductions in heart-failure events and clinically meaningful KCCQ symptom score gains (Packer 2025 NEJM, PMID 39555826). The SUMMIT cardiac MRI substudy quantified left-ventricular mass reduction and paracardiac adipose tissue reduction with tirzepatide versus placebo, demonstrating structural cardiac remodeling consistent with the symptomatic benefit (Pandey 2025 JACC, PMID 39566869). A separate SUMMIT secondary analysis in Nature Medicine showed reductions in markers of circulatory overload and end-organ damage (Borlaug 2025, PMID 39551891). Subsequent SUMMIT subgroup papers showed consistent benefit across CKD status (Banerjee 2025 JACC, PMID 40162940), BMI strata (Borlaug 2025 JACC, PMID 40701669), and diabetes status (2025 JACC stratified analysis, PMID 40903131). The mechanism likely combines weight loss, reduced epicardial adiposity, lower inflammation, and improved hemodynamics. None of this is medical advice.

Question 9

I have HF with an EF of 45% (mildly reduced). Which trial applies to me?

Accepted Answer

Heart failure with mildly reduced ejection fraction (HFmrEF), defined as EF 41-49%, sits in the middle of the two main GLP-1 evidence buckets and is best covered by the pooled SELECT+FLOW+STEP-HFpEF+STEP-HFpEF DM analysis published in the Lancet (Kosiborod 2024, PMID 39222642). That pooled analysis explicitly enrolled patients with mildly reduced or preserved ejection fraction and showed consistent reductions in cardiovascular death and HF events with semaglutide across the EF spectrum from roughly 40% upward. The STEP-HFpEF (PMID 37622681) and STEP-HFpEF DM (PMID 38587233) trials enrolled patients with EF 45% or greater, so they cover the upper half of HFmrEF. The SELECT prespecified HF analysis included patients with HFmrEF and showed CV benefit regardless of EF (Deanfield 2024 Lancet, PMID 39181597). SUMMIT for tirzepatide enrolled EF 50% or greater per the HFpEF definition. For patients in the HFmrEF range, Reddit threads describe semaglutide as the more evidence-supported option today because its trials explicitly captured this EF range. None of this is medical advice.

Question 10

Was heart failure an exclusion in SUSTAIN-6 or SELECT, and what does that mean for me?

Accepted Answer

Neither SUSTAIN-6 nor SELECT excluded heart failure broadly. SUSTAIN-6 was the cardiovascular outcomes trial of semaglutide in type 2 diabetes patients with established CV disease or high CV risk and enrolled 3,297 patients, a substantial fraction of whom had a heart failure history at baseline (Marso 2016 NEJM, PMID 27633186). The trial showed a 26% reduction in the primary MACE endpoint and the heart-failure subgroup did not appear to drive harm. SELECT randomized 17,604 patients with overweight or obesity and established cardiovascular disease but without diabetes to semaglutide 2.4 mg weekly versus placebo and showed a 20% reduction in MACE (Lincoff 2023 NEJM, PMID 37952131). The prespecified SELECT heart failure analysis confirmed CV benefit in the 4,286 patients with prevalent heart failure at baseline regardless of ejection fraction (Deanfield 2024 Lancet, PMID 39181597). The 2021 Sattar Lancet meta-analysis pooling all GLP-1 cardiovascular outcomes trials reported a 11% reduction in heart-failure hospitalization across the class in T2D populations (PMID 34425083). For a Reddit user with stable heart failure considering a GLP-1, the trial inclusion criteria are unusually generous. None of this is medical advice.

Questions and answers